These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25641231)

  • 1. Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value.
    Stirzaker C; Zotenko E; Song JZ; Qu W; Nair SS; Locke WJ; Stone A; Armstong NJ; Robinson MD; Dobrovic A; Avery-Kiejda KA; Peters KM; French JD; Stein S; Korbie DJ; Trau M; Forbes JF; Scott RJ; Brown MA; Francis GD; Clark SJ
    Nat Commun; 2015 Feb; 6():5899. PubMed ID: 25641231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
    Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and clinicopathologic correlates of O⁶-methylguanine-DNA methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugs.
    Fumagalli C; Della Pasqua S; Bagnardi V; Cardillo A; Sporchia A; Colleoni M; Viale G; Barberis M; Pruneri G
    Clin Breast Cancer; 2014 Aug; 14(4):285-90. PubMed ID: 24709436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the breast cancer methylome using formalin-fixed paraffin-embedded tumour.
    Wong EM; Joo JE; McLean CA; Baglietto L; English DR; Severi G; Wu HC; Terry MB; Hopper JL; Milne RL; Giles GG; Southey MC
    Breast Cancer Res Treat; 2016 Nov; 160(1):173-180. PubMed ID: 27604360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
    Gupta S; Jaworska-Bieniek K; Narod SA; Lubinski J; Wojdacz TK; Jakubowska A
    Breast Cancer Res Treat; 2014 Dec; 148(3):615-22. PubMed ID: 25376744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
    Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
    Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer.
    Gao Y; Wang X; Li S; Zhang Z; Li X; Lin F
    Med Sci Monit; 2021 May; 27():e930025. PubMed ID: 34003815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
    Ignatov T; Poehlmann A; Ignatov A; Schinlauer A; Costa SD; Roessner A; Kalinski T; Bischoff J
    Breast Cancer Res Treat; 2013 Sep; 141(2):205-12. PubMed ID: 24026861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief reports: A distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome.
    El Helou R; Wicinski J; Guille A; Adélaïde J; Finetti P; Bertucci F; Chaffanet M; Birnbaum D; Charafe-Jauffret E; Ginestier C
    Stem Cells; 2014 Nov; 32(11):3031-6. PubMed ID: 25069843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.
    Staaf J; Glodzik D; Bosch A; Vallon-Christersson J; Reuterswärd C; Häkkinen J; Degasperi A; Amarante TD; Saal LH; Hegardt C; Stobart H; Ehinger A; Larsson C; Rydén L; Loman N; Malmberg M; Kvist A; Ehrencrona H; Davies HR; Borg Å; Nik-Zainal S
    Nat Med; 2019 Oct; 25(10):1526-1533. PubMed ID: 31570822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation biomarkers for noninvasive detection of triple-negative breast cancer using liquid biopsy.
    Manoochehri M; Borhani N; Gerhäuser C; Assenov Y; Schönung M; Hielscher T; Christensen BC; Lee MK; Gröne HJ; Lipka DB; Brüning T; Brauch H; Ko YD; Hamann U
    Int J Cancer; 2023 Mar; 152(5):1025-1035. PubMed ID: 36305646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk.
    Li J; Chen Y; Yu H; Tian J; Yuan F; Fan J; Liu Y; Zhu L; Wang F; Zhao Y; Pang D
    Sci Rep; 2017 Feb; 7():43011. PubMed ID: 28220843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide DNA methylation profiling in triple-negative breast cancer reveals epigenetic signatures with important clinical value.
    Stirzaker C; Zotenko E; Clark SJ
    Mol Cell Oncol; 2016 Jan; 3(1):e1038424. PubMed ID: 27308556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of dysregulated microRNAs in triple-negative breast cancer (review).
    Yang F; Zhang W; Shen Y; Guan X
    Int J Oncol; 2015 Mar; 46(3):927-32. PubMed ID: 25571912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring breast carcinogenesis through integrative genomics and epigenomics analyses.
    Minning C; Mokhtar NM; Abdullah N; Muhammad R; Emran NA; Ali SA; Harun R; Jamal R
    Int J Oncol; 2014 Nov; 45(5):1959-68. PubMed ID: 25175708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions.
    Martins AT; Monteiro P; Ramalho-Carvalho J; Costa VL; Dinis-Ribeiro M; Leal C; Henrique R; Jerónimo C
    Breast Cancer Res Treat; 2011 Aug; 129(1):1-9. PubMed ID: 20842524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs-mediated cell fate in triple negative breast cancers.
    Sui X; Wang X; Han W; Li D; Xu Y; Lou F; Zhou J; Gu X; Zhu J; Zhang C; Pan H
    Cancer Lett; 2015 May; 361(1):8-12. PubMed ID: 25748387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico recognition of a prognostic signature in basal-like breast cancer patients.
    Conte F; Sibilio P; Grimaldi AM; Salvatore M; Paci P; Incoronato M
    PLoS One; 2022; 17(2):e0264024. PubMed ID: 35167614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer.
    Zhang C; Han Y; Huang H; Min L; Qu L; Shou C
    Int J Oncol; 2014 Jun; 44(6):2025-33. PubMed ID: 24676531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
    Maierthaler M; Kriegsmann M; Peng C; Jauch S; Szabo A; Wallwiener M; Rom J; Sohn C; Schneeweiss A; Sinn HP; Yang R; Burwinkel B
    Exp Mol Pathol; 2015 Aug; 99(1):180-7. PubMed ID: 26112095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.